CLINICAL TRIALS PROFILE FOR BROMFENAC SODIUM

All Clinical Trials for BROMFENAC SODIUM

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00198445 ↗	Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract Surgery	Completed	Bausch & Lomb Incorporated	Phase 3	2003-05-01	The primary objective of this study was to investigate the efficacy of bromfenac sodium ophthalmic solution 0.09% for treatment of post-operative ocular inflammation in subjects who undergo cataract extraction and intraocular lens implantation. The secondary objective was to investigate the safety and tolerability of the same.
NCT00595543 ↗	Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%	Completed	Bp Consulting, Inc	Phase 4	2008-01-01	To compare bromfenac 0.09%, diclofenac sodium 0.1%, and ketorolac tromethamine 0.5% ophthalmic solutions for the treatment of acute pseudophakic CME after cataract surgery.
NCT01387464 ↗	Aqueous Humor Concentration of InSite Vision (ISV) 303 (Bromfenac in DuraSite) to Bromday Once Daily (QD) Prior to Cataract Surgery	Completed	InSite Vision	Phase 2	2011-07-01	The purpose of this study is to evaluate the aqueous humor concentration of bromfenac sodium in subjects administered multiple topical ocular doses of ISV-303 or Bromday™ QD prior to routine cataract surgery.
NCT01387464 ↗	Aqueous Humor Concentration of InSite Vision (ISV) 303 (Bromfenac in DuraSite) to Bromday Once Daily (QD) Prior to Cataract Surgery	Completed	Sun Pharma Global FZE	Phase 2	2011-07-01	The purpose of this study is to evaluate the aqueous humor concentration of bromfenac sodium in subjects administered multiple topical ocular doses of ISV-303 or Bromday™ QD prior to routine cataract surgery.
NCT02017197 ↗	Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil	Completed	Fundação de Amparo à Pesquisa do Estado de São Paulo	Phase 4	2014-08-01	The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.
NCT02017197 ↗	Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil	Completed	Federal University of São Paulo	Phase 4	2014-08-01	The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.

Clinical Trial Conditions for BROMFENAC SODIUM

Condition Name

Condition Name for BROMFENAC SODIUM
Intervention	Trials
Cataract	3
Atrial Fibrillation	1
Familial Exudative Vitreoretinopathies	1
Postoperative Complications	1

Condition MeSH

Condition MeSH for BROMFENAC SODIUM
Intervention	Trials
Cataract	3
Inflammation	1
Retinal Diseases	1
Familial Exudative Vitreoretinopathies	1

Clinical Trial Locations for BROMFENAC SODIUM

Trials by Country

Trials by Country for BROMFENAC SODIUM
Location	Trials
United States	25
China	1
Brazil	1

Trials by US State

Trials by US State for BROMFENAC SODIUM
Location	Trials
Pennsylvania	2
Idaho	1
Georgia	1
Florida	1
Connecticut	1

Clinical Trial Progress for BROMFENAC SODIUM

Clinical Trial Phase

Clinical Trial Phase for BROMFENAC SODIUM
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	1
Phase 2	2

Clinical Trial Status

Clinical Trial Status for BROMFENAC SODIUM
Clinical Trial Phase	Trials
Completed	5
Not yet recruiting	1

Clinical Trial Sponsors for BROMFENAC SODIUM

Sponsor Name

Sponsor Name for BROMFENAC SODIUM
Sponsor	Trials
Bausch & Lomb Incorporated	1
Bp Consulting, Inc	1
InSite Vision	1

Sponsor Type

Sponsor Type for BROMFENAC SODIUM
Sponsor	Trials
Other	6
Industry	3